Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 6/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16751022 | 1.00 | ATM (0.59) | ATMPIK3CDMMP2ANPEPDPP4 | |
| SCHEMBL1923005 | 0.82 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL3673559 | 0.82 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL17760540 | 0.82 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL4531927 | 0.82 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL25286686 | 0.82 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL746205 | 0.82 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL744198 | 0.82 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL5795993 | 0.82 | ATM (0.48) | ATMPIK3CDDPP4DPP8DPP9 | |
| SCHEMBL17511120 | 0.80 | ATM (0.42) | ATMPIK3CDDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006037-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2022-06-01 | — | — | EP | disclosed |
| EP-2616808-B1 | PROLYL ENDOPEPTIDASE PROBES | STANFORD RES INST INT (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2616808-B1 | PROLYL ENDOPEPTIDASE PROBES | STANFORD RES INST INT (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8835423-B2 | Azepine inhibitors of janus kinases | INCYTE CORPORATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | INCYTE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-8563541-B2 | Azepine inhibitors of Janus kinases | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-8268855-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-18 | — | — | US | disclosed |
| WO-2012037044-A2 | PROLYL ENDOPEPTIDASE PROBES | SRI INTERNATIONAL (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | SRI INTERNATIONAL | 2012-03-15 | — | — | US | disclosed |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | SRI INTERNATIONAL | 2012-03-15 | — | — | US | disclosed |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | SRI INTERNATIONAL | 2012-03-15 | — | — | US | disclosed |
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7737279-B2 | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210629-A1 | 1,6-DIHYDRO-1,3,5,6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | IL1R1, IDO1, TLR1 | ATM 4193/4885PIK3CD 2901/4885MMP2 4526/4885 |
| US-20120065103-A1 | Prolyl Endopeptidase Probes | PREP, XPNPEP1, ANPEP | ATM 4306/4885PIK3CD 4414/4885MMP2 104/4885 |
| US-20140031344-A1 | AZEPINE INHIBITORS OF JANUS KINASES | JAK1, JAK3, JAK2 | ATM 540/4885PIK3CD 559/4885MMP2 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.